Athira Pharma, Inc.
ATHA
$4.14
-$0.08-1.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.63M | 24.88M | 26.09M | 26.86M | 27.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.89M | 78.62M | 96.78M | 111.85M | 121.40M |
| Operating Income | -57.89M | -78.62M | -96.78M | -111.85M | -121.40M |
| Income Before Tax | -59.85M | -79.75M | -96.94M | -109.22M | -113.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.85 | -79.75 | -96.94 | -109.22 | -113.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.85M | -79.75M | -96.94M | -109.22M | -113.45M |
| EBIT | -57.89M | -78.62M | -96.78M | -111.85M | -121.40M |
| EBITDA | -56.92M | -77.65M | -95.81M | -110.88M | -120.43M |
| EPS Basic | -15.46 | -20.68 | -25.21 | -28.49 | -29.70 |
| Normalized Basic EPS | -9.01 | -12.27 | -15.13 | -17.50 | -18.92 |
| EPS Diluted | -15.46 | -20.68 | -25.21 | -28.49 | -29.70 |
| Normalized Diluted EPS | -9.01 | -12.27 | -15.13 | -17.50 | -18.92 |
| Average Basic Shares Outstanding | 15.54M | 15.46M | 15.39M | 15.33M | 15.29M |
| Average Diluted Shares Outstanding | 15.54M | 15.46M | 15.39M | 15.33M | 15.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |